Overview

Effect of Pyridorin in Patients With Diabetic Nephropathy

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
Phase:
Phase 2
Details
Lead Sponsor:
BioStratum
Treatments:
Pyridoxamine